We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Retaane® in Age-Related Macular Degeneration

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00569569
First Posted: December 7, 2007
Last Update Posted: December 7, 2007
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Rudolf Foundation Clinic
December 5, 2007
December 7, 2007
December 7, 2007
February 2006
Not Provided
Increase in VA [ Time Frame: 6 months ]
Same as current
No Changes Posted
Decrease in Macula Edema [ Time Frame: 6 months ]
Same as current
Not Provided
Not Provided
 
Retaane® in Age-Related Macular Degeneration
Retaane® in Age-Related Macular Degeneration

The treatment of fibrotic choroidal neovascular lesions with presence of residual peripheral activity in age related macular degeneration currently presents a great challenge. With visual loss threatening, there are only very few therapeutic options.

While these patients are neither suitable for laser therapy nor for photodynamic therapy with Verteporfin, antiangiogenic drugs applied intravitreally are now available.

Some patients however reject this therapeutic option because of potential complications such as endophthalmitis and the frequency of necessary injections. 20 patients who rejected intravitreal therapy were treated with Anecortave acetate (Retaane®) which was applied as a juxtascleral depot injection.

Not Provided
Interventional
Phase 2
Phase 3
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Age Related Macular Degeneration
Drug: juxtascleral depot injection of Retaane
juxtascleral depot injection of Retaane
Experimental: 1
Patients treated with Retaane
Intervention: Drug: juxtascleral depot injection of Retaane
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
20
March 2007
Not Provided

Inclusion Criteria:

  • rejection of intravitreal injections
  • presence of fibrotic choroidal neovascular lesions with presence of residual peripheral activity in age related macular degeneration

Exclusion Criteria:

  • conditions precluding judgement of the fundus
Sexes Eligible for Study: All
20 Years to 90 Years   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
 
NCT00569569
RFC012007
No
Not Provided
Not Provided
Not Provided
Rudolf Foundation Clinic
Not Provided
Study Chair: Susanne Binder, M.D. no affiliation
Rudolf Foundation Clinic
December 2007

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP